Patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM) who were treated with aficamten vs. placebo saw significantly greater improvement in exercise capacity and self-reported ...

Roxana Mehran, MD, FACC, today assumed the role of president of the American College of Cardiology. Mehran will serve a one-year term at the helm of the almost 60,000-member global cardiovascular ...

Clinicians will increasingly encounter heart rhythm data generated from consumer-grade devices. Consumer-grade smartphone-paired devices and smartwatches have very high sensitivity and specificity for ...

Spironolactone, an aldosterone blocker, compared with placebo, did not show any significant improvement in terms of heart failure (HF) hospitalizations and cardiovascular death at 24 months in ...

Multiple 2025 guideline updates reshape pediatric heart failure, pulmonary hypertension, and adult congenital heart disease management. Early signal data suggest sodium-glucose cotransporter-2 ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

The U.S. Food and Drug Administration (FDA) has approved the Sapien 3, Sapien 3 Ultra and Sapien 3 Ultra Resilia TAVR valves from Edwards Lifesciences to treat patients with asymptomatic severe aortic ...

In the ASPIRED trial, which was simultaneously published in NEJM, 14-day ambulatory ECG monitoring in patients with unexplained syncope after evaluation in the emergency department did not ...

Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) who were treated with eplontersen, a once-monthly transthyretin gene silencer, experienced no significant difference in ...

The addition of AZD5462, an oral once-daily relaxin family peptide receptor 1 agonist, was well tolerated among individuals with well-treated chronic heart failure (HF), based on findings from ...

Researchers presenting findings from the AIR-STEMI trial at ESC Congress 2026 said a strategy of complete coronary artery revascularization guided by functional coronary angiography resulted in a ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...